* If you want to update the article please login/register
"In the final analysis of the study, participants in the control group will receive their fourth dose of mRNA COVID-19 vaccine and will have their blood drawn 28 days post-vaccination. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT04978038
"Study Design: This is a phase 1, open-label, dose-escalation trial to determine the risks and effectiveness of administering gp91-Grans to adult patients with X-linked CGD and to determine the maximum tolerated dose. " Subjects will be subjected to granulocyte-enriched apheresis to produce cell products for mRNA-correction and then receive one administration of the study agent. The first subjects will be hospitalized for at least three days after administration, and then to a third and then third dose level for subsequent subjects. In patients with CGD, the study found that administering mRNA-transfected autologous granulocyte-enriched apheresis product to restore protein expression and phagocyte nicotide oxidase function. Study Agent Description: The study agent is one administration of autologous CGD granulocyte-enriched cells enriched with granulocyte-enriched cells, also known as gp91-Grans. Each subject will be at least 1 week between the study agent administration and the test subject. MTD is defined as the highest dose level that does not result in the same grade 3 or 4 AEs in 3 or more patients. Secondary Endpoints: Determine percent of circulating dihydrorhodamine positive granulocytes following study agent infusion. Following study agent infusion or disappearance of DHR+ granulocytes, serial measurement of circulating DHR+ granulocytes from peripheral blood until day 3 of study agent infusion or disappearance of DHR+ granulocytes from peripheral blood has been published.
Source link: https://clinicaltrials.gov/ct2/show/NCT05189925
"The present test-negative design research aims to determine the true-world impact of Pfizer-BioNTech BNT162b2 mRNA vaccine on symptomatic SARS-CoV-2 disease and its consequences among children aged 5 to 11 years in Toledo, Southern Brazil," the city of Toledo in Southern Brazil. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT05403307
"In patients with multiple sclerosis who are treated with immune modulating drugs, cell-mediated and antibody-mediated immunity to the COVID-19, SARS-CoV-2 virus following vaccination with mRNA vaccine. " Hundreds of people have died from a single vaccine injection a few days after the first vaccine injection, 45, 90, and 180 days since the first vaccine injection. They will also be asked to donate 30 mL of whole blood 28-42 days after the booster injection date. The analysis of T cell responses to SARS-CoV-2 spike peptides will be performed using isolated peripheral blood lymphocytes. Responses will be compared to 10 participants who have been accepted in the CORVax spike plasmid DNA vaccine trial and are then referred to as "health controls"" in this study. ".
Source link: https://clinicaltrials.gov/ct2/show/NCT04796584
Participants will be randomly assigned to receive quadrivalent inactivated influenza vaccine and mRNA COVID vaccine either simultaneously or sequentially, 14 days apart during this research. Participants in the first dose of mRNA COVID vaccine receiving their first dose of mRNA COVID vaccine will be administered either 3 or 4 weeks after the first dose. There will not be a second dose of mRNA COVID vaccine for those receiving a third dose.
Source link: https://clinicaltrials.gov/ct2/show/NCT05028361
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions